Gene Therapy Startup Raises $42M for Huntington's Trial

A gene therapy startup founded by a leading children's hospital researcher just raised $42 million to bring two promising treatments to patients who desperately need them.

Latus Bio is launching clinical trials this year for genetic diseases that rob children and adults of their futures. The company's work focuses on conditions where faulty genes cause progressive loss of movement, vision, and cognitive ability.

The first trial targets CLN2 disease, a rare form of Batten disease that typically appears in early childhood. Kids with this condition experience seizures, lose their vision, and face declining brain function. Latus expects initial results from this trial by the end of 2026.

The new funding allows the company to open a second front in the fight against genetic disease. Latus will now move forward with trials for Huntington's disease, a devastating condition that causes uncontrolled movements and mental decline, usually starting in a person's 30s or 40s.

Beverly Davidson, chief scientific strategy officer at the Children's Hospital of Philadelphia, founded the company. Her team is working to avoid setbacks that have affected other gene therapy developers in this space.

Gene therapy works by delivering working copies of genes to replace faulty ones. For families living with these conditions, each new trial represents a chance at treatments that could slow or stop disease progression.

The Ripple Effect

The $42 million investment signals growing confidence in gene therapy's potential to tackle previously untreatable diseases. Every successful trial builds knowledge that researchers can apply to other genetic conditions.

Huntington's disease alone affects about 30,000 Americans, with another 200,000 at risk of inheriting it. CLN2 disease is rarer but equally devastating, typically leading to death in childhood or early adolescence.

The trials launching this year join a growing wave of gene therapy research. Scientists have made remarkable progress in the past decade, turning theoretical treatments into real medicines that change lives.

For families watching loved ones decline from these genetic diseases, clinical trials offer something precious: hope grounded in science. The work happening at Latus Bio could eventually give doctors tools to fight back against conditions they can only manage today.

As these trials move forward, they'll test not just the treatments but also new approaches that could make gene therapy safer and more effective for everyone.